Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.44 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.44 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22927126 | 1.00 | CYP17A1 (0.49) | CYP17A1MAP4K4TRPV1BCL2BECN1 | |
| SCHEMBL23011276 | 0.80 | LMNA (0.42) | KDM4E | |
| SCHEMBL13857260 | 0.79 | GPR39 (0.56) | CYP3A4KDM4E | |
| SCHEMBL26078072 | 0.78 | LMNA (0.42) | KDM4E | |
| SCHEMBL18570243 | 0.77 | CYP17A1 (0.61) | CYP17A1MAP4K4BCL2BECN1PSMB8 | |
| SCHEMBL25432469 | 0.75 | CYP17A1 (0.55) | CYP17A1MAP4K4 | |
| SCHEMBL13931410 | 0.74 | CYP17A1 (0.52) | CYP17A1MAP4K4BCL2BECN1 | |
| SCHEMBL18680023 | 0.74 | KDM4E (0.57) | KDM4E | |
| SCHEMBL19275985 | 0.74 | KDM4E (0.61) | KDM4E | |
| SCHEMBL12956832 | 0.74 | KDM4E (0.61) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024560-A1 | STRONGLY POLARIZED MOLECULE, AND SINGLE MOLECULE FIELD EFFECT TRANSISTOR PREPARED THEREFROM | PEKING UNIVERSITY (CN) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024560-A1 | STRONGLY POLARIZED MOLECULE, AND SINGLE MOLECULE FIELD EFFECT TRANSISTOR PREPARED THEREFROM | CHRM1, CHRM2, CHRM4 | CYP17A1 2068/4885MAP4K4 1634/4885TRPV1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.